Business

Aridis Pharmaceuticals said that “an undisclosed pharmaceutical company” has agreed to pay $6.5 million plus annual royalty payments for Aridis’ AR-501 nebulized gallium for the treatment of chronic lung infections in patients with cystic fibrosis.… Read more . . .

Intranasal drug developer Orexo and Swedish vaccine developer Abera Bioscience have announced that they will collaborate on development of intranasal dry powder vaccines based on Orexo’s AmorphOX powder engineering technology and Abera’s vaccine platform, starting… Read more . . .

Qnovia announced that it has raised $16 million in Series B financing for development of its QN-01 nicotine inhaler for smoking cessation in the UK. In the US, the FDA recently approved Qnovia’s IND for… Read more . . .

Virpax Pharmaceuticals announced the extension of a research and development agreement with an institute of the National Institutes of Health (NIH) related to the company’s NES100 enkephalin nasal spray for the treatment of acute and… Read more . . .

Pulmatrix has announced a planned merger with biopharma Cullgen, which is developing oral protein degraders for the treatment of various indications. In anticipation of the merger, Pulmatrix says that it will divest inhalation assets, including… Read more . . .

Danish pharma company ALK says that it is paying ARS Pharmaceuticals $145 million up front and up to $320 million in potential milestone payments plus royalties for the rights to neffy intranasal adrenaline (epinephrine) everywhere except the… Read more . . .

French vaccine developer Vaxinano announced that it has raised €6 million to support clinical development of several intranasal vaccine candidates based on the Stellar-NP nanoparticle platform. The company’s pipeline includes nasal vaccines against zoonotic diseases… Read more . . .

Agomab Therapeutics said that it has closed an $89 million Series D financing round that will support development of several candidates, including its AGMB-447 inhaled ALK5 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF).… Read more . . .